Price reduction for a number of heavyweight varieties (with list)

Medical Network January 26th, the golden age of foreign enterprises, to pass? A 54% drop recently, Pfizer announced a big price cut for its product, Ebersyn (generic name Berbersili), from 29,799 yuan to 13,667 yuan per bottle, a 54% reduction.
same time, Pfizer phased out previous charitable grants for low- and low-income patients.
if according to the common dosing program, the specification is 125mg of Aboxin once a day, take 21 days in a row, after 7 days of drug suspension, 28 days for a treatment cycle.
price reduction, the monthly treatment cost of patients in about 30,000 yuan, if there is a charity drug, monthly treatment costs in about 17,000 yuan.
price reduction, the monthly treatment cost fell to about 13,000 yuan.
In fact, this is the first price reduction since Aibo's new listing, or because it failed to enter the 2020 health insurance catalog, since the media drug Sla analysis, the main reason is that its competitors are either just listed, failed to include in the health care negotiations;
as the world's first cell cycle protein-dependent kinase (CDK) 4/6 inhibitor, the field of advanced breast cancer is a significant breakthrough innovative therapy, Aibo new filled the gap in the targeted treatment of HR/HER2-advanced breast cancer.
, new sales have grown at a rapid rate since the listing, reaching $700 million in 2015, $2 billion in 2016, $3 billion in 2017 and $4.118 billion in 2018, up 32% year-on-year, according to data.
the present, the combination of pyrethroids has become a first-line therapy for patients with ER-/HER2-breast cancer, and the future market is expected to be very positive, with the breast cancer market second only to Roche.
December 14, 2020, Qilu Pharmaceuticals China's first generic pyrithroid capsule was approved for market treatment by China's NMPA.
in addition to Pfizer and Qilu, 13 companies, including Haussen, Hengrui, Haizheng and Zhengda Tianqing, are conducting clinical trials, according to the China New Drug Research and Development Monitoring Database

In the days when similar products were not yet on the market, Pfizer did not cut prices by 70 per cent, as its foreman Hessetin did, but cut them by 54 per cent, slightly above the average, or in terms of capacity.
more health insurance varieties, price reduction not only did not enter the health insurance varieties, into the health insurance varieties of the price reduction has already begun.
January 14, according to the Gansu Provincial Public Resources Trading Bureau issued a notice on the adjustment of the price of some drugs on the internet, in which Lilly's Baritinib tablets 2mg price was reduced from 3998 yuan to 1064 yuan, a drop of more than 73.3%, the degree of sugar peptide injection 1.5mg:0 .5ml from 840 yuan / branch to 298 yuan / branch, Jiangsu Haussen polyglycol losena peptide injection (specification: 0.5ml: 0.2mg / branch) hanging net limit price from 395 yuan / branch adjusted to 187 yuan / branch.
According to the enterprise's active application, the enterprise is now actively applying for price reduction of the four drugs published, the publicity period is January 15 to January 19, no objection during the publicity period in accordance with the implementation date of the introduction of the platform, publicity of objections automatically transferred to the next processing process, not adjusted.
adjusted prices will be implemented throughout the province as of January 20, 2021.
For enterprises to take the initiative to reduce prices, commitment to sell at the lowest price in the country or a lower price, medical institutions may purchase at the promised price, not higher than the promised price of procurement and sales (may be equal to the promised price).
and Gansu Province is far from the first of these varieties to reduce prices in the region: January 12, Shaanxi Province Public Resources Trading Center issued a notice on the adjustment of some products to limit the price of the network, according to enterprise applications, Jiangsu Haussen polyglycol losenathe peptide injection (0.5ml:0.0.) 2mg / branch) hanging net limit price from 395 yuan / branch adjusted to 187 yuan / branch, Beijing Science Park Xinhai Pharmaceutical Management Co. , Ltd. agent of the fluorine for the United States to inhale powder foggy net limit price from 900 yuan / box to 239 yuan / box.
January 11, Jilin issued a notice on reducing the price of Jiangsu Haussen polyglycol losena peptide injection, the polyglycol locena peptide injection (0.5ml: 0.2mg) to 187 yuan / box, 0.5ml: 0.1mg specification of the product from 295 yuan / box to 110 yuan / box.
January 11, Henan Province also issued a notice to adjust the price limits of three drugs, the dose of saccharide injections and fluorotide inhalation powder mist.
health care negotiations varieties are understood to be Lilly's lactose peptide injections, barrettini tablets, Haussen's polyglycol locena peptide injections and other products through the 2020 negotiations, into the health insurance catalog, the new payment price is expected to be formally implemented in March this year, although the negotiating price has not yet been announced, but through this price adjustment to make a prejudgment of the final results. Lilly's dose of saccharide injections was approved by the State Drug Administration in February 2019 to enter the Chinese market for blood sugar control in adults with type 2 diabetes, including single-drug and medications for metformin and/or sulfonylurea to treat patients who still have poor blood sugar control, according to
meter net data.
2014, Lilly's saccharide peptides were approved for sale and have been successfully listed in more than 70 countries, including the Americas, Europe and Asia.
2018, the company has global sales of $3.2 billion, the highest-paid product for Lilly.
from Pfizer and Lilly's actions, multinational drug companies will enter China with innovative drugs, will adopt a high-pricing strategy, to leave enough room for negotiation and profit.
whether or not to enter health insurance, if you want to compete and imitations under the attack of the domestic market, price reduction is the only way.
drug research drug after the patent expires by generic drugs quickly, a large proportion of replacement, is the normal situation of the global drug market.
, however, in the domestic market after the expiration of many of the original research drugs still maintain a high market share, which is called foreign enterprises? Golden age?.
but predictably, the golden age of high prices for foreign companies may no longer exist, with the multi-means overlay effect of volume procurement, consistent evaluation and health care fee control.